See more : Yotta Acquisition Corporation (YOTA) Income Statement Analysis – Financial Results
Complete financial analysis of BeiGene, Ltd. (688235.SS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BeiGene, Ltd., a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
- Ai Holdings Corporation (3076.T) Income Statement Analysis – Financial Results
- Mahesh Developers Limited (MAHESH.BO) Income Statement Analysis – Financial Results
- Star Equity Holdings, Inc. (STRR) Income Statement Analysis – Financial Results
- Cavalier Resources Limited (CVR.AX) Income Statement Analysis – Financial Results
- Shandong Yanggu Huatai Chemical Co., Ltd. (300121.SZ) Income Statement Analysis – Financial Results
BeiGene, Ltd. (688235.SS)
About BeiGene, Ltd.
BeiGene Ltd. is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.46B | 1.42B | 1.18B | 308.87M | 428.21M | 198.22M | 238.39M | 1.07M | 8.82M | 13.04M | 11.15M |
| Cost of Revenue | 379.92M | 1.93B | 1.62B | 1.37B | 998.53M | 707.71M | 273.99M | 98.03M | 58.25M | 21.86M | 13.46M |
| Gross Profit | 2.08B | -511.06M | -447.86M | -1.06B | -570.32M | -509.49M | -35.61M | -96.96M | -49.43M | -8.83M | -2.32M |
| Gross Profit Ratio | 84.55% | -36.09% | -38.07% | -342.10% | -133.19% | -257.03% | -14.94% | -9,061.96% | -560.73% | -67.72% | -20.77% |
| Research & Development | 1.78B | 1.64B | 1.46B | 1.29B | 927.34M | 679.01M | 269.02M | 98.03M | 58.25M | 21.86M | 13.46M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 195.39M | 62.60M | 20.10M | 7.31M | 6.93M | 3.14M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.50B | 1.28B | 990.12M | 600.18M | 388.25M | 195.39M | 62.60M | 20.10M | 7.31M | 6.93M | 3.14M |
| Other Expenses | 3.50M | 751.00K | 750.00K | 846.00K | 1.33M | 1.99M | 11.46M | -2.49M | -916.00K | 600.00K | 584.00K |
| Operating Expenses | 3.29B | 1.28B | 990.87M | 601.02M | 389.58M | 196.28M | 62.85M | 20.10M | 7.31M | 6.93M | 3.14M |
| Cost & Expenses | 3.67B | 3.21B | 2.62B | 1.97B | 1.39B | 903.99M | 336.84M | 118.13M | 65.56M | 28.79M | 16.61M |
| Interest Income | 0.00 | 52.48M | 15.76M | 2.00M | 9.13M | 13.95M | 0.00 | 0.00 | 559.00K | 40.00K | 2.00K |
| Interest Expense | 0.00 | 52.48M | 0.00 | 0.00 | 0.00 | 13.95M | 0.00 | 383.00K | 1.23M | 3.55M | 3.16M |
| Depreciation & Amortization | 87.68M | 66.28M | 46.46M | 31.79M | 18.62M | 10.39M | 4.76M | 1.91M | 1.55M | 1.56M | 1.59M |
| EBITDA | -1.12B | -1.72B | -1.39B | -1.63B | -941.27M | -695.38M | -93.70M | -115.15M | -55.20M | -14.20M | -3.15M |
| EBITDA Ratio | -45.55% | -126.34% | -122.25% | -536.41% | -223.85% | -355.60% | -41.21% | -10,940.19% | -643.66% | -104.03% | -29.42% |
| Operating Income | -1.21B | -1.79B | -1.44B | -1.66B | -959.89M | -705.77M | -98.46M | -117.06M | -56.75M | -15.76M | -5.46M |
| Operating Income Ratio | -49.12% | -126.40% | -122.31% | -536.69% | -224.16% | -356.05% | -41.30% | -10,940.19% | -643.66% | -120.88% | -48.96% |
| Total Other Income/Expenses | 381.90M | -171.37M | 147.00K | 39.49M | 16.31M | 15.94M | 7.39M | -2.10M | -357.00K | -2.79M | -2.44M |
| Income Before Tax | -825.84M | -1.96B | -1.44B | -1.62B | -943.59M | -689.83M | -91.06M | -119.16M | -57.10M | -18.55M | -7.89M |
| Income Before Tax Ratio | -33.59% | -138.50% | -122.30% | -523.90% | -220.35% | -348.01% | -38.20% | -11,136.73% | -647.71% | -142.28% | -70.81% |
| Income Tax Expense | 55.87M | 42.78M | -25.23M | -17.67M | 6.99M | -15.80M | 2.24M | 54.00K | -2.10M | 3.88M | 3.34M |
| Net Income | -881.71M | -2.00B | -1.41B | -1.60B | -950.58M | -673.77M | -93.11M | -119.22M | -57.10M | -18.28M | -7.49M |
| Net Income Ratio | -35.86% | -141.52% | -120.15% | -518.18% | -221.99% | -339.91% | -39.06% | -11,141.78% | -647.71% | -140.22% | -67.22% |
| EPS | -8.45 | -1.49 | -1.17 | -1.47 | -1.22 | -0.93 | -0.17 | -0.30 | -0.14 | -0.03 | -0.01 |
| EPS Diluted | -8.45 | -1.49 | -1.17 | -1.47 | -1.22 | -0.93 | -0.17 | -0.30 | -0.14 | -0.03 | -0.01 |
| Weighted Avg Shares Out | 104.39M | 1.34B | 1.21B | 1.09B | 780.70M | 720.75M | 543.19M | 403.62M | 409.72M | 684.59M | 684.59M |
| Weighted Avg Shares Out (Dil) | 104.39M | 1.34B | 1.21B | 1.09B | 780.70M | 720.75M | 543.19M | 403.62M | 409.72M | 684.59M | 684.59M |
Source: https://incomestatements.info
Category: Stock Reports